Harry W Herr1, Tanya N Milan2, Guido Dalbagni2. 1. Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: herrh@mskcc.org. 2. Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: Patients with recurrent or persistent high-grade non-muscle-invasive bladder cancer after bacille Calmette-Guérin (BCG) therapy are termed "BCG failures." We hypothesize that BCG-refractory patients who fail to respond to BCG have worse outcomes after bladder-sparing treatments compared with BCG-relapsing patients whose tumors recur after at least a 6-month disease-free interval. MATERIALS AND METHODS: We screened 32 patients who had failed BCG therapy for eligibility in a multicenter investigational trial. BCG-refractory patients received instillations of a mycobacterial cell wall-DNA complex extract. BCG-relapsing patients were treated with additional BCG or other intravesical agents. Both groups of patients were followed prospectively with transurethral biopsy after 6 months, and cystoscopy every 3 to 6 months for more than 2 years. Median follow-up time for all patients was 53 months (range: 24-72 mo). RESULTS: Seventeen patients were classified as BCG refractory and 15 patients defined BCG relapsing. Recurrence-free median survival time was 10 months for BCG-refractory patients receiving mycobacterial cell wall-DNA complex vs. 23 months for BCG-relapsing patients who received another induction course of BCG therapy (P = 0.002). Progression-free survival time was 18 months for BCG-refractory vs. 52 months for BCG-relapsing patients (P = 0.001). Of the 17 BCG-refractory patients, 8 (47%) have died vs. 3 (20%) of the 15 BCG-relapsing patients. CONCLUSIONS: BCG-refractory and BCG-relapsing categories differentiate BCG-failed patients into high-and lower-risk prognostic groups that may be useful in guiding treatment strategies.
PURPOSE:Patients with recurrent or persistent high-grade non-muscle-invasive bladder cancer after bacille Calmette-Guérin (BCG) therapy are termed "BCG failures." We hypothesize that BCG-refractory patients who fail to respond to BCG have worse outcomes after bladder-sparing treatments compared with BCG-relapsing patients whose tumors recur after at least a 6-month disease-free interval. MATERIALS AND METHODS: We screened 32 patients who had failed BCG therapy for eligibility in a multicenter investigational trial. BCG-refractory patients received instillations of a mycobacterial cell wall-DNA complex extract. BCG-relapsing patients were treated with additional BCG or other intravesical agents. Both groups of patients were followed prospectively with transurethral biopsy after 6 months, and cystoscopy every 3 to 6 months for more than 2 years. Median follow-up time for all patients was 53 months (range: 24-72 mo). RESULTS: Seventeen patients were classified as BCG refractory and 15 patients defined BCG relapsing. Recurrence-free median survival time was 10 months for BCG-refractory patients receiving mycobacterial cell wall-DNA complex vs. 23 months for BCG-relapsing patients who received another induction course of BCG therapy (P = 0.002). Progression-free survival time was 18 months for BCG-refractory vs. 52 months for BCG-relapsing patients (P = 0.001). Of the 17 BCG-refractory patients, 8 (47%) have died vs. 3 (20%) of the 15 BCG-relapsing patients. CONCLUSIONS: BCG-refractory and BCG-relapsing categories differentiate BCG-failed patients into high-and lower-risk prognostic groups that may be useful in guiding treatment strategies.
Authors: Ashish M Kamat; Richard J Sylvester; Andreas Böhle; Joan Palou; Donald L Lamm; Maurizio Brausi; Mark Soloway; Raj Persad; Roger Buckley; Marc Colombel; J Alfred Witjes Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Charles C Peyton; Juan Chipollini; Mounsif Azizi; Ashish M Kamat; Scott M Gilbert; Phillippe E Spiess Journal: World J Urol Date: 2018-12-07 Impact factor: 3.661
Authors: Patrick Vianna Garcia; Fábio Rodrigues Ferreira Seiva; Amanda Pocol Carniato; Wilson de Mello Júnior; Nelson Duran; Alda Maria Macedo; Alexandre Gabarra de Oliveira; Rok Romih; Iseu da Silva Nunes; Odilon da Silva Nunes; Wagner José Fávaro Journal: BMC Cancer Date: 2016-07-07 Impact factor: 4.430
Authors: Esmee I M L Liem; Joyce Baard; Evelyne C C Cauberg; Mieke T J Bus; D Martijn de Bruin; M Pilar Laguna Pes; Jean J M C H de la Rosette; Theo M de Reijke Journal: Med Oncol Date: 2017-09-02 Impact factor: 3.064